Including pro-inflammatory and anti-inflammatory targets relevant to IEC-HS—such as IFN-γ, IL-6, IL-10, IL-1β, TNF-α, IL-18, CXCL9, and CXCL10.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Immune effector cell-associated HLH-like syndrome (IEC-HS) is an emerging complication observed in cell-based immunotherapies such as CAR-T cell therapy. Characterized by systemic inflammation, hypercytokinemia, and excessive immune activation, IEC-HS shares pathological parallels with classical hemophagocytic lymphohistiocytosis (HLH), including elevated interferon-gamma (IFN-γ), interleukin-18 (IL-18), and other macrophage activation–associated cytokines.
Precise quantification of these cytokines is crucial for modeling IEC-HS mechanisms, understanding immune trajectory during CAR-T administration, and optimizing immunotherapeutic constructs to mitigate toxicity.
Fig.1 Pathophysiology of HLH.1
Creative Biolabs offers a dedicated IEC-HS Cytokine Detection Service developed for researchers focused on CAR-T-associated immune toxicities. This service provides quantitative measurement of key inflammatory mediators involved in HLH-like pathophysiology, using internally validated multiplex or single-target assay platforms, with flexibility across sample types and species.
Including pro-inflammatory and anti-inflammatory targets relevant to IEC-HS—such as IFN-γ, IL-6, IL-10, IL-1β, TNF-α, IL-18, CXCL9, and CXCL10.
Analysis of surrogate indicators like soluble CD25 (sCD25), ferritin, and soluble CD163 to aid immune state interpretation.
Available for murine, human, or non-human primate (NHP) research applications, suitable for translational immunology models.
Compatible with serum, plasma, cell culture supernatants, and PBMC lysates.
High-sensitivity detection with strong signal linearity for dynamic range analysis.
This service supports both time-course experiments and endpoint analyses, providing comprehensive insight into cytokine kinetics during CAR-T expansion, persistence, or toxicity phases.
Cytokines included are selected based on literature-supported relevance to HLH-like inflammation and CAR-T–induced immune activation cascades.
Our detection systems are adaptable, using internal assay configurations optimized for high signal clarity and low cross-reactivity.
Ideal for monitoring cytokine fluctuations across multiple experimental timepoints in in vivo or ex vivo models.
Designed to integrate with our immunophenotyping and genomic profiling platforms to support multiplexed immune landscape studies.
Optional statistical packages include fold-change calculations, clustering analysis, and visualization such as heatmaps and cytokine trajectory plots.
Q1: Which cytokines are most indicative of IEC-HS in CAR-T models?
A1: Markers such as IFN-γ, IL-18, IL-6, CXCL9, and ferritin are consistently elevated in HLH-like responses and are included in our standard panel.
Q2: Can I tailor a panel for my model system?
A2: Yes. We offer fully customizable panels based on the species and cytokines of interest for your study design.
Q3: What types of samples are accepted?
A3: We accept serum, plasma, PBMC lysates, and cell culture supernatants. Sample integrity is assessed before testing.
Q4: Is quantitative comparison between groups supported?
A4: Absolutely. Our service includes absolute quantification and can include comparative statistical analysis upon request.
Creative Biolabs is your collaborative partner in exploring immune-related adverse events in CAR-T and immune effector cell-based research. Our team of scientific experts is dedicated to advancing cytokine profiling methodologies to support mechanistic understanding and toxicity management.
We welcome partnerships with academic researchers, biotech innovators, and translational immunology teams. Whether you're investigating HLH-like syndromes, refining CAR-T constructs, or modeling inflammatory kinetics, our tailored services will help you generate meaningful, reproducible data.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
